Myocardial protective effect of Shenfu injection in patients undergoing valve replacement

Abstract

To investigate the myocardial protective effect of Shenfu injection in patients undergoing valve replacement. Forty patients undergoing valve replacement surgery under cardio-pulmonary bypass (CPB) were randomly divided into two equal groups: group C (control group, given with 4:1 blood containing cardioplegic liquid during the CPB) and group SF (Shenfu injection, receiving the blood containing cardioplegic liquid with 20 ml/L of Shenfu injection additionally). Blood samples were withdrawn from the central vein before operation, 30 minutes after aorta declamping, and 4, 12, and 24 hours after CPB, to test the serum cardiac troponin I (cTnI), creatine phosphokinase (CK), and creatine phosphokinase isoenzyme (CK-MB). The CK, CK-MB, and cTnI level were normal before operation and there were no significant differences in these indexes between the two groups. 30 minutes after aorta declamping, the CK, CK-MB, and cTnI levels were higher than those before operation in both groups (P < 0.05, P < 0. 01), and the higher levels remained to 24 hours after CPB. 24 hours after CPB, the CK level of the group SF was significantly lower than that of the group C (P < 0.05), and 30 minutes after aorta declamping to 24 h after CPB, the CK-MB and cTnI levels were lower in the group SF compared with the group C (all P < 0. 05). Shenfu injection decreases the level of CK, CK-MB and cTnI, and reduces the myocardial injury.